Overview
Neuromyelitis Optica is treated with 2 medications in our database, including Enspryng, UPLIZNA. 2 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Genentech, Amgen. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Neuromyelitis Optica treatment below.
Also known as:
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsMassachusetts General Hospital — PHASE4
Amgen
Hoffmann-La Roche — PHASE3
Mohamed Moshref abd alsattar
Assiut University
Tianjin Medical University General Hospital — PHASE4
Tianjin Medical University General Hospital — PHASE1, PHASE2
Xiamen Hospital of Traditional Chinese Medicine
First Affiliated Hospital of Chongqing Medical University
Tianjin Medical University General Hospital — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableEnspryng
* Patient Copay Amount: As little as $0 per prescription * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Patients must have commercial (private) insurance; must
UPLIZNA
* Patient Copay Amount: As little as $0 out-of-pocket for UPLIZNA and infusion costs * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Must be a resident of the
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
9 grantsPAN Foundation Neuromyelitis Optica Spectrum Disorder Patient Assistance Grant
PAN Foundation
Applicants must be receiving treatment for NMOSD in the United States, have health insurance covering a qualifying medication, and have an income at or below 500% of the Federal Poverty Level. This copay grant provides an initial $4,000 with a total annual cap of $8,000 for covered prescription costs.
Amgen Patient Assistance Program
Amgen
The provided text contains no content to analyze for eligibility requirements. The document title and source suggest a collection of financial aid resources for patients with bone marrow failure diseases.
NORD RareCare Patient Assistance Program
National Organization for Rare Disorders, Inc. (NORD)
Community
No community posts yet. Be the first to share your experience with Neuromyelitis Optica.
Start the conversation →Latest news about Neuromyelitis Optica
Disease timeline:
New recruiting trial: Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
A new clinical trial is recruiting patients for Neuromyelitis Optica
New recruiting trial: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
A new clinical trial is recruiting patients for Neuromyelitis Optica
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Neuromyelitis Optica
What is Neuromyelitis Optica?
Neuromyelitis Optica is treated with 2 medications in our database, including Enspryng, UPLIZNA. 2 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Genentech, Amgen. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Neuromyelitis Optica treatment below.
How is Neuromyelitis Optica inherited?
Neuromyelitis Optica follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Neuromyelitis Optica typically begin?
Typical onset of Neuromyelitis Optica is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Neuromyelitis Optica?
Yes — 20 recruiting clinical trials are currently listed for Neuromyelitis Optica on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Neuromyelitis Optica?
25 specialists and care centers treating Neuromyelitis Optica are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Neuromyelitis Optica?
2 FDA-approved treatments and 2 patient support programs are currently tracked on UniteRare for Neuromyelitis Optica. See the treatments and support programs sections for copay assistance, eligibility, and contact details.